TOKYO, May 13 (Pulse News Wire) – Wolves Hand CO.,LTD. (194A.T) reported a significant increase in revenue for its fiscal third quarter ending June 2026, driven by strategic acquisitions and operational efficiencies.
Revenue reached ¥4.318 billion, marking a 12.4% rise compared to the same period last year. Operating profit surged by 43.8%, reaching ¥674 million, despite temporary expenses related to the acquisition of See Inc. and increased personnel costs. The company's strong performance was bolstered by cost synergies and improved pricing strategies across its existing hospitals and newly acquired entities, Bahati Inc., Asuka Medical Inc., and See Inc.
Additionally, the firm’s capital structure remained robust, with a self-capital ratio increasing to 38.4%. In further strategic moves, WOLVES HAND established a joint research institute aimed at drug development and product creation through partnerships with major pharmaceutical companies, leveraging its extensive clinical data and patient base. Dr. Yoshihisa Okamoto, a renowned veterinarian, was appointed to lead this initiative, enhancing the company's capabilities in advanced veterinary medical research and development.
🟡 Confidence: Standard AI-translated content.